子宫内膜癌组织LAPTM4B-35和LRG1表达变化及其临床意义
|
摘要
目的探讨溶酶体相关4次跨膜蛋白B-35(LAPTM4B-35)和富亮氨酸α2糖蛋白1(LRG1)在子宫内膜癌发生、发展中的作用。方法选取86例子宫内膜癌患者手术切除的子宫内膜癌组织及其癌旁正常组织,采用real-time PCR法检测LAPTM4B-35、LRG1 mRNA表达。分析子宫内膜癌组织LAPTM4B-35、LRG1 mRNA表达与患者临床病理参数的关系。以子宫内膜癌组织LAPTM4B-35、LRG1 mRNA相对表达量的均数为界值,将患者分为LAPTM4B-35、LRG1高表达者与低表达者,比较不同LAPTM4B-35、LRG1表达者5年生存率。结果子宫内膜癌组织LAPTM4B-35、LRG1 mRNA相对表达量均明显高于癌旁正常组织(P均<0. 05)。子宫内膜癌组织LAPTM4B-35mRNA表达与组织病理分级、浸润深度、淋巴结转移和临床分期相关(P均<0. 05),LRG1 mRNA表达与淋巴结转移和临床分期相关(P均<0. 05)。LAPTM4B-35、LRG1高表达者术后5年生存率及术后生存时间均低于LAPTM4B-35、LRG1低表达者(P均<0. 05)。结论 LAPTM4B-35、LRG1高表达可促进子宫内膜癌的发生及发展,并与患者不良预后有关。
引文
[1]Kong F,Gao F,Chen J,et al. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-smallcell lung cancer[J]. Oncotarget,2016,7(35):56193-56199.
[2] Meng H,Song Y,Zhu J,et al. LRG1 promotes angiogenesis through upregulating the TGF-β1pathway in ischemic rat brain[J]. Mol Med Rep,2016,14(6):5535-5543.
[3]Zhang H,Tian B,Yu H,et al. LAPTM4B-35 protein as a potential therapeutic target in gastric cancer[J]. Tumour Biol,2014,35(12):12737-12742.
[4]Meng F,Li H,Zhou R,et al. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis[J]. Biomarkers,2013,18(2):136-143.
[5]Shaker O,Taha F,Salah M,et al. LAPTM4B gene expression and polymorphism as diagnostic markers of breast cancer in egyptian patients[J]. J Med Biochem,2015,34(4):393-401.
[6]Zhai G,Yang H,Ji X,et al. Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients[J]. Med Oncol,2012,29(4):2744-2749.
[7]杨洋. LAPTM4B基因多态性与人类肿瘤的关系[J].实用肿瘤学杂志,2013,27(2):172-176.
[8]Meng Y,Wang L,Xu J,et al. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis,while reducing chemotherapy sensitivity[J]. Mol Oncol,2018,12(3):373-390.
[9]Kang Y,Yin M,Jiang W,et al. Overexpression of LAPTM4B-35is associated with poor prognosis in colorectal carcinoma[J]. Am J Surg,2012,204(5):677-683.
[10]张静怡,单丽珠,张洁,等. LAPTM4B-35和MMP-9在胃癌中表达及临床意义[J].中国肿瘤临床,2017,44(24):1226-1231.
[11]郭佳,刘修恒,王敏,等.溶酶体相关4次跨膜蛋白质β基因在前列腺癌组织的表达及临床意义[J].中华实验外科杂志,2015,32(12):2964-2966.
[12]Dong X,Tamura K,Kobayashi D,et al. LAPTM4B-35 is a novel prognostic factor for glioblastoma[J]. J Neurooncol,2017,132(2):295-303.
[13]孙德聪,石燕,吕瑶,等.恶性肿瘤抗血管生成潜在靶点LRG1研究进展[J].胃肠病学和肝病学杂志,2017,26(5):598-600.
[14]王永平,李芬,郑安元,等.富亮氨酸α2糖蛋白1(LRG1)在肿瘤中的研究进展[J].现代生物医学进展,2017,17(7):1371-1374.
[15]刘兆国,范方田,赵林钢,等.肿瘤血管生成新靶点LRG1研究进展[J].中国药理学通报,2014,30(1):6-9.
[2] Meng H,Song Y,Zhu J,et al. LRG1 promotes angiogenesis through upregulating the TGF-β1pathway in ischemic rat brain[J]. Mol Med Rep,2016,14(6):5535-5543.
[3]Zhang H,Tian B,Yu H,et al. LAPTM4B-35 protein as a potential therapeutic target in gastric cancer[J]. Tumour Biol,2014,35(12):12737-12742.
[4]Meng F,Li H,Zhou R,et al. LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis[J]. Biomarkers,2013,18(2):136-143.
[5]Shaker O,Taha F,Salah M,et al. LAPTM4B gene expression and polymorphism as diagnostic markers of breast cancer in egyptian patients[J]. J Med Biochem,2015,34(4):393-401.
[6]Zhai G,Yang H,Ji X,et al. Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients[J]. Med Oncol,2012,29(4):2744-2749.
[7]杨洋. LAPTM4B基因多态性与人类肿瘤的关系[J].实用肿瘤学杂志,2013,27(2):172-176.
[8]Meng Y,Wang L,Xu J,et al. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis,while reducing chemotherapy sensitivity[J]. Mol Oncol,2018,12(3):373-390.
[9]Kang Y,Yin M,Jiang W,et al. Overexpression of LAPTM4B-35is associated with poor prognosis in colorectal carcinoma[J]. Am J Surg,2012,204(5):677-683.
[10]张静怡,单丽珠,张洁,等. LAPTM4B-35和MMP-9在胃癌中表达及临床意义[J].中国肿瘤临床,2017,44(24):1226-1231.
[11]郭佳,刘修恒,王敏,等.溶酶体相关4次跨膜蛋白质β基因在前列腺癌组织的表达及临床意义[J].中华实验外科杂志,2015,32(12):2964-2966.
[12]Dong X,Tamura K,Kobayashi D,et al. LAPTM4B-35 is a novel prognostic factor for glioblastoma[J]. J Neurooncol,2017,132(2):295-303.
[13]孙德聪,石燕,吕瑶,等.恶性肿瘤抗血管生成潜在靶点LRG1研究进展[J].胃肠病学和肝病学杂志,2017,26(5):598-600.
[14]王永平,李芬,郑安元,等.富亮氨酸α2糖蛋白1(LRG1)在肿瘤中的研究进展[J].现代生物医学进展,2017,17(7):1371-1374.
[15]刘兆国,范方田,赵林钢,等.肿瘤血管生成新靶点LRG1研究进展[J].中国药理学通报,2014,30(1):6-9.